- Home
- AFCG vs NKTX Comparison
AFCG vs NKTX Comparison
Compare AFCG & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- NKTX
- Stock Information
- Founded
- AFCG 2020
- NKTX 2015
- Country
- AFCG United States
- NKTX United States
- Employees
- AFCG N/A
- NKTX N/A
- Industry
- AFCG Real Estate Investment Trusts
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- AFCG Real Estate
- NKTX Health Care
- Exchange
- AFCG Nasdaq
- NKTX Nasdaq
- Market Cap
- AFCG 127.4M
- NKTX 123.5M
- IPO Year
- AFCG 2021
- NKTX 2020
- Fundamental
- Price
- AFCG $4.41
- NKTX $2.17
- Analyst Decision
- AFCG Buy
- NKTX Strong Buy
- Analyst Count
- AFCG 7
- NKTX 6
- Target Price
- AFCG $11.00
- NKTX $14.40
- AVG Volume (30 Days)
- AFCG 143.4K
- NKTX 558.0K
- Earning Date
- AFCG 08-14-2025
- NKTX 08-12-2025
- Dividend Yield
- AFCG 20.86%
- NKTX N/A
- EPS Growth
- AFCG 84.02
- NKTX N/A
- EPS
- AFCG 0.96
- NKTX N/A
- Revenue
- AFCG $41,036,509.00
- NKTX N/A
- Revenue This Year
- AFCG N/A
- NKTX N/A
- Revenue Next Year
- AFCG $17.96
- NKTX N/A
- P/E Ratio
- AFCG $4.61
- NKTX N/A
- Revenue Growth
- AFCG N/A
- NKTX N/A
- 52 Week Low
- AFCG $4.32
- NKTX $1.31
- 52 Week High
- AFCG $10.88
- NKTX $6.74
- Technical
- Relative Strength Index (RSI)
- AFCG 41.69
- NKTX 61.21
- Support Level
- AFCG $4.50
- NKTX $1.74
- Resistance Level
- AFCG $4.74
- NKTX $2.32
- Average True Range (ATR)
- AFCG 0.16
- NKTX 0.15
- MACD
- AFCG 0.00
- NKTX 0.02
- Stochastic Oscillator
- AFCG 0.00
- NKTX 72.22
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.